CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

21 7 2022 15:05:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

10 5 2022 06:30:02 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

05 5 2022 15:05:03 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

26 4 2022 06:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

10 3 2022 15:05:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

03 3 2022 15:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

13 1 2022 17:30:00 提供 Nasdaq GlobeNewswire

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

13 12 2021 08:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

12 11 2021 06:00:02 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

10 11 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

02 11 2021 15:05:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

01 11 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

27 10 2021 15:05:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

22 9 2021 05:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

07 9 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

16 8 2021 16:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

02 8 2021 15:05:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

15 7 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

25 5 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

05 5 2021 08:00:01 提供 Nasdaq GlobeNewswire